One of the underlying rationales for giving preoperative therapy to patients with pancreatic cancer is to select those with rapidly progressive disease, particularly those who are not anticipated to benefit from an operation, prior to undergoing what would otherwise be a complex and potentially morbid operation, says Katz. Watch here. . .
Matthew H.G. Katz, MD, FACS, associate professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the benefit of neoadjuvant chemotherapy in patients with pancreatic cancer.